Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 8/20 | 0.74 |
| ▸ | RET | P07949 | 6/20 | 0.74 |
| ▸ | ALK | Q9UM73 | 4/20 | 0.74 |
| ▸ | FLT3 | P36888 | 3/20 | 0.74 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.74 |
| ▸ | CSF1R | P07333 | 2/20 | 0.74 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.74 |
| ▸ | SRC | P12931 | 2/20 | 0.74 |
| ▸ | FLT1 | P17948 | 2/20 | 0.74 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.74 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.74 |
| ▸ | FLT4 | P35916 | 2/20 | 0.74 |
| ▸ | NPC1 | O15118 | 2/20 | 0.74 |
| ▸ | MAPT | P10636 | 2/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.74 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.74 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.74 |
| ▸ | MEN1 | O00255 | 1/20 | 0.74 |
| ▸ | GMNN | O75496 | 1/20 | 0.74 |
| ▸ | USP2 | O75604 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5200799 | 1.00 | KDR (0.74) | KDRRETALKFLT3PDGFRB | |
| Semaxanib SCHEMBL29373311 | 0.85 | RET (1.00) | KDRRETALKFLT3PDGFRB | |
| Semaxanib SCHEMBL28266617 | 0.85 | RET (1.00) | KDRRETALKFLT3PDGFRB | |
| Semaxanib SCHEMBL19571 | 0.85 | RET (1.00) | KDRRETALKFLT3PDGFRB | |
| Semaxanib SCHEMBL19572 | 0.85 | RET (1.00) | KDRRETALKFLT3PDGFRB | |
| Semaxanib SCHEMBL29351025 | 0.85 | RET (1.00) | KDRRETALKFLT3PDGFRB | |
| SCHEMBL14468825 | 0.80 | KDR (0.74) | KDRRETALKFLT3PDGFRB | |
| SCHEMBL4188870 | 0.80 | KDR (0.63) | KDRRETALKFLT3PDGFRB | |
| SCHEMBL6001617 | 0.80 | KDR (0.67) | KDRRETALKFLT3PDGFRB | |
| SCHEMBL6001621 | 0.80 | KDR (0.67) | KDRRETALKFLT3PDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1259234-B9 | 3-HETEROARYLIDENYL-2-INDOLINONE COMPOUNDS FOR MODULATING PROTEIN KINASE ACTIVITY AND FOR USE IN CANCER CHEMOTHERAPY | SUGEN INC (US) | 2007-02-14 | — | — | EP | claimed |
| US-20030191162-A1 | 3-heteroarylidenyl-2-indolinone compounds for modulating protein kinase activity and for use in cancer chemotherapy | SUGEN INC. | 2003-10-09 | — | — | US | claimed |
| US-20030073837-A1 | 3-HETEROARYLIDENYL-2-INDOLINONE COMPOUNDS FOR MODULATING PROTEIN KINASE ACTIVITY AND FOR USE IN CANCER CHEMOTHERAPY | SUGEN, INC. | 2003-04-17 | — | — | US | claimed |
| EP-1259234-B9 | 3-HETEROARYLIDENYL-2-INDOLINONE COMPOUNDS FOR MODULATING PROTEIN KINASE ACTIVITY AND FOR USE IN CANCER CHEMOTHERAPY | SUGEN INC (US) | 2007-02-14 | — | — | EP | disclosed |
| EP-1259234-B1 | 3-HETEROARYLIDENYL-2-INDOLINONE COMPOUNDS FOR MODULATING PROTEIN KINASE ACTIVITY AND FOR USE IN CANCER CHEMOTHERAPY | SUGEN INC (US) | 2006-08-16 | — | — | EP | disclosed |
| US-20030191162-A1 | 3-heteroarylidenyl-2-indolinone compounds for modulating protein kinase activity and for use in cancer chemotherapy | SUGEN INC. | 2003-10-09 | — | — | US | disclosed |
| US-20030073837-A1 | 3-HETEROARYLIDENYL-2-INDOLINONE COMPOUNDS FOR MODULATING PROTEIN KINASE ACTIVITY AND FOR USE IN CANCER CHEMOTHERAPY | SUGEN, INC. | 2003-04-17 | — | — | US | disclosed |
| EP-1259234-A1 | 3-HETEROARYLIDENYL-2-INDOLINONE COMPOUNDS FOR MODULATING PROTEIN KINASE ACTIVITY AND FOR USE IN CANCER CHEMOTHERAPY | Sugen, Inc. (US) | 2002-11-27 | — | — | EP | disclosed |
| WO-2001049287-A1 | 3-HETEROARYLIDENYL-2-INDOLINONE COMPOUNDS FOR MODULATING PROTEIN KINASE ACTIVITY AND FOR USE IN CANCER CHEMOTHERAPY | SUGEN, INC. (US) | 2001-07-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073837-A1 | 3-HETEROARYLIDENYL-2-INDOLINONE COMPOUNDS FOR MODULATING PROTEIN KINASE ACTIVITY AND FOR USE IN CANCER CHEMOTHERAPY | DCK, TNK2, MKNK1 | KDR 2091/4885RET 882/4885ALK 2093/4885 |
| US-20030191162-A1 | 3-heteroarylidenyl-2-indolinone compounds for modulating protein kinase activity and for use in cancer chemotherapy | DCK, TNK2, MKNK1 | KDR 2091/4885RET 882/4885ALK 2093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.